Does Alpha-ketoglutarate Supplementation Lower BiologicaL agE in Middle- Aged Adults?

Last updated: May 20, 2026
Sponsor: National University of Singapore
Overall Status: Active - Not Recruiting

Phase

2

Condition

Aging

Treatment

Ca-AKG

Clinical Study ID

NCT05706389
NUS-IRB-2021-946
  • Ages 40-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Geroscience is an emerging interdisciplinary field of study in gerontological sciences. With emphasis on understanding the mechanistic drivers of aging, it seeks translational approaches that could eventually be applied to improve human healthspan and delay age-associated chronic diseases. Contrary to popular opinion that aging is irreversible, advances in geroscience research have demonstrated that aging is modifiable and inhibiting or activating specific molecular pathways can improve healthspan and extend lifespan in model organisms. Advocates of geroscience take the view that age-related chronic diseases are best treated by slowing the aging process, rather than using the prevailing disease-centric approach of addressing each disease alone. Thus, the concept is that biological aging, rather than chronological aging, is amenable to intervention.

In this regard, geroscientists are at the forefront of longevity medicine in rigorously testing novel supplements, drugs and other prophylactics that can enhance healthspan. Some of these interventions involve repurposing existing drugs such as rapamycin, a well-known immunosuppressant, at different dosing regimens to specifically target biological hallmarks of aging.

This study will investigate the effects of alpha-ketoglutarate (AKG), an endogenous metabolite, on biomarkers of aging in middle-aged residents of Singapore.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • participants whose biological age (as measured by blood DNA methylation) is greaterthan their chronological age

Exclusion

Exclusion Criteria:

  • pregnant women

  • more than ONE of the following chronic medical conditions (based on the medicalhistory and during screening), they are NOT eligible to participate in the study:

  1. Waist circumference more than or equal to 90 cm for males or more than or equalto 80 cm for females

  2. Fasting triglycerides more than or equal to 1.7 mmol/l

  3. High-density lipoprotein less than 1.0 mmol/l in men or less than 1.3 mmol/l inwomen

  4. Blood pressure more than or equal to 130/85 mmHg or use of antihypertensivemedication

  5. Fasting glucose more than or equal to 6.0 mmol/l

  6. Osteopenia

  7. Mild Osteoarthritis not interfering in daily activities

  8. Fatty liver

  • Participants will NOT be recruited if they fall in the following categories:

  1. Pre-existing, or history of major CVD (coronary artery disease, heart failure,stroke, peripheral vascular disease, pulmonary hypertension),severe/uncontrolled hypertension (under 3 or more than 3 prescribedmedications), rheumatic heart disease, congenital heart disease, deep veinthrombosis, pulmonary embolism

  2. Type 1 diabetes and Type 2 diabetes under oral metformin or insulin therapy andwith diabetic complications such as diabetic retinopathy, diabetic nephropathy

  3. Active cancer or treatment of cancer in the last 3 years

  4. Chronic obstructive pulmonary disease (COPD), severe asthma (taking dailymedications)

  5. Pregnant women will not be recruited into this study because of the safetyissues associated with X-ray irradiation during DXA scan

  6. Potential female participants who plan on pregnancy within the next 9 months ofstudy period

  7. Multiple sclerosis and autoimmune/immune deficiency diseases such as Rheumaticarthritis, HIV, Crohn's disease

  8. Recent history of sepsis or infection (within 3 months of in-patienthospitalization)

  9. Any psychiatric disease or neurodegenerative diseases such as Alzheimer'sDisease, Parkinson's Disease, Lewy body dementia, and any eating disorders

  10. Any metal implants in the body

  11. Hepatitis and Liver cirrhosis (independent of severity)

  12. Severe kidney disease (GFR less than 30 ml/min/1.73 m2)

  13. Skin disease (on oral or systemic medication for immune system)

  14. Subjects receiving any other similar investigational product within 60 days or 5 halflives before the screening, whichever that is longer

  15. Any serious medical illness which in the PI's judgment may jeopardize thesubject by his or her participation in this study or may hamper his or herability to perform and complete procedures required in the study

Study Design

Total Participants: 120
Treatment Group(s): 1
Primary Treatment: Ca-AKG
Phase: 2
Study Start date:
February 24, 2023
Estimated Completion Date:
January 15, 2027

Study Description

Recent growing understanding on mechanisms of aging as gradual changes in body systems through several cellular and molecular levels has raised research interests in the biology of aging. There are seven established overlapping processes of aging: oxidative stress, macromolecular damage, epigenetic changes, abnormal metabolism, impaired proteostasis, decline in stem cell functions and inflammation. These overlapping changes over the lifetime affect the onset of age-related diseases and possibly the aging process itself. However, lifestyle and pharmacologic interventions can modify the deterioration of aging pathways. AKG is a generally regarded as safe (GRAS) micronutrient and has shown great potential in extending healthspan. Here, we aim to study the role of AKG in the modulation of aging.

The aim is to evaluate the anti-aging function of AKG and determine whether AKG can modulate biological pathways of aging in middle-aged adults in Singapore. Our hypothesis is that AKG will affect DNA methylation which will be associated with the change in blood biomarkers of aging and change in physiological function. It allows us to study the longitudinal effects of AKG on clinical and biological outcomes.

This is a 6-month double-blinded, placebo-controlled longitudinal interventional study on middle-aged participants to study the effect of AKG on biomarkers of aging, with another 3 months of post-intervention follow-up. The total duration of participation in this study is 9 months.

The rationale for this study design is to study the long-term effect of 1 g AKG in middle-aged adults. Our study design of 6 months of intervention (1 g AKG vs placebo) will allow us to understand the effect of AKG treatment on DNA methylation, and another 3 months of post-intervention follow-up will help us understand if there is any long-term effect of AKG. In order to minimize recruitment bias, our study design is double-blinded.

Connect with a study center

  • Centre for Healthy Longevity, Alexandra Hospital

    Singapore, 159964
    Singapore

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.